Overview

In 2018, Paul Peter Tak left his many roles (including SVP and chief immunology officer) at GlaxoSmithKline to join Flagship Pioneering as a venture partner. In an interview with Scrip, he discusses what prompted him to make the leap. He’s already CEO of an “undisclosed biotech start-up operating in stealth mode.” Find out more about his other roles at Flagship. Learn more about Flagship’s approach–creating think tanks to build companies from scratch around important unmet challenges–and why Tak finds that so appealing. Gain insights into what Tak means when he talks about “following the science.”